JMIR Publications

ABSTRACT

Aging is an inevitable and universal phenomenon characterized by the decline of physiological systems, making organisms more vulnerable to a variety of age-related diseases. This decline is driven by cumulative cellular damage, oxidative stress, inflammation, and impaired cellular repair mechanisms, leading to increased fragility of tissues and organs. Cardiovascular diseases, such as coronary artery disease, hypertension, and strokes, are particularly common in the elderly, often resulting from atherosclerosis. Neurodegenerative diseases like Alzheimer's and Parkinson's, which involve the progressive loss of neurons, also significantly impact cognitive function and motor coordination in aging populations. Metabolic disorders, including type 2 diabetes and osteoporosis, are closely associated with aging. Type 2 diabetes impairs glucose regulation, while osteoporosis reduces bone density, increasing the risk of fractures. These conditions, along with cancer, arthritis, macular degeneration, and hearing loss, contribute to the overall decline in physical and cognitive function as individuals age. Although aging and its associated disorders cannot be entirely prevented, researchers are focused on understanding the underlying mechanisms to develop treatments that promote healthy aging. Personalized therapies, genetic medicine, biotechnology, regular exercise, a balanced diet, and social engagement are recognized as essential strategies for maintaining health and well-being into old age. In response to the challenges posed by aging, Google launched Calico (California Life Company) in 2013, aiming to improve health during the final years of life by exploring the biology of aging and developing therapies to combat age-related diseases. Led by Arthur D. Levinson, Calico’s research strategy includes large-scale genomic and proteomic studies, as well as the use of model organisms to identify key biochemical processes involved in aging. The company is actively developing therapies for cancer, neurological diseases, cardiovascular conditions, and other age-related disorders through collaborations with academic institutions and biotech companies. Calico also utilizes data analytics and machine learning to identify biomarkers of aging, discover new therapeutic targets, and predict individual responses to treatments. This data-driven approach accelerates the discovery process in aging biology and helps prioritize research initiatives. While the goal of achieving immortality remains out of reach, Calico's efforts align with the principles of promoting healthy aging and extending the health span, positioning the company at the forefront of longevity research and offering significant promise for transforming the aging experience.